Novartis AG
NVS
$164.67
$2.001.23%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 54.53B | 54.35B | 53.26B | 51.72B | 50.32B |
| Total Other Revenue | 2.14B | 2.02B | 1.92B | 1.50B | 1.41B |
| Total Revenue | 56.67B | 56.37B | 55.19B | 53.22B | 51.72B |
| Cost of Revenue | 13.62B | 13.39B | 13.09B | 12.94B | 12.82B |
| Gross Profit | 43.05B | 42.98B | 42.10B | 40.28B | 38.91B |
| SG&A Expenses | 13.24B | 13.30B | 13.13B | 12.78B | 12.56B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 404.00M | -676.00M | 32.00M | 292.00M | 518.00M |
| Total Operating Expenses | 37.95B | 36.20B | 35.96B | 35.48B | 35.41B |
| Operating Income | 18.73B | 20.18B | 19.23B | 17.75B | 16.31B |
| Income Before Tax | 16.35B | 16.42B | 15.61B | 14.92B | 13.64B |
| Income Tax Expenses | 2.39B | 2.04B | 1.97B | 2.06B | 1.70B |
| Earnings from Continuing Operations | 13.97K | 14.38K | 13.64K | 12.86K | 11.94K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 17.00M | 10.00M | 16.00M | -1.00M | 2.00M |
| Net Income | 13.98B | 14.39B | 13.65B | 12.86B | 11.94B |
| EBIT | 18.73B | 20.18B | 19.23B | 17.75B | 16.31B |
| EBITDA | 23.19B | 24.64B | 23.60B | 22.08B | 20.66B |
| EPS Basic | 7.21 | 7.36 | 6.91 | 6.43 | 5.92 |
| Normalized Basic EPS | 5.66 | 6.18 | 5.84 | 5.35 | 4.85 |
| EPS Diluted | 7.15 | 7.31 | 6.86 | 6.39 | 5.88 |
| Normalized Diluted EPS | 5.62 | 6.13 | 5.80 | 5.31 | 4.82 |
| Average Basic Shares Outstanding | 7.76B | 7.83B | 7.92B | 8.00B | 8.08B |
| Average Diluted Shares Outstanding | 7.81B | 7.88B | 7.97B | 8.06B | 8.13B |
| Dividend Per Share | 4.67 | 3.86 | 3.86 | 3.86 | 3.86 |
| Payout Ratio | 55.91% | 54.32% | 57.26% | 60.27% | 63.85% |